Potrero Medical Receives FDA Breakthrough Device Designation for Accuryn AKI Predict Algorithm

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

HAYWARD, Calif., Sept. 13, 2022 /PRNewswire/ -- Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.

Metadata

Provider:

PR Newswire

Retrieved on:

Tuesday, September 13, 2022

Information

Tags:

Disease, Intelligence, Technology, Health, AKI, Kidney, Acute kidney injury, Diagnosis, FDA, IAH, Medicine, Patient, Medical imaging, Medical device

Geotags:

CALIFORNIA

Organisation:

POTRERO MEDICAL, INC.

Summary

Key Points:

HAYWARD, Calif., Sept. 13, 2022 /PRNewswire/ -- Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.
Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside."
To receive breakthrough designation from the FDA, there are several criteria that must be met.
First, the device must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.

Potrero Medical Receives FDA Breakthrough Device Designation for Accuryn AKI Predict Algorithm

HAYWARD, Calif., Sept. 13, 2022 /PRNewswire/ -- Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.

"We are excited about the designation, and what this means for patients, providers and health systems" Joe Urban, CEO

Joe Urban, Potrero CEO stated "We celebrate the breakthrough designation, and we are excited about what this will mean for patients, providers and health systems in the future." Urban further commented "Continuous urine output and intra-abdominal pressure are new patient parameters that, until Accuryn, have not been available to leverage as critical data streams. Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside."

To receive breakthrough designation from the FDA, there are several criteria that must be met. First, the device must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Next, the device must meet one of the following: 2a) it represents breakthrough technology, 2b) no approved or cleared alternative exists, 2c) it offers significant advantages over existing approved or cleared alternatives, or 2d) device availability is in the best interest of patients.

About Potrero Medical

Potrero Medical, Inc. is a personalized platform transforming patient care through precision fluid management and analytics that offer clinical decision support by providing precise data from the kidney. Potrero Medical was founded with a mission to improve patient care and save health systems money with the latest advances in artificial intelligence and sensors. Potrero Medical is headquartered in Hayward, CA. For more information, visit potreromed.com

Contacts

Media Relations:
Myria Crawford
Sr. Director of Marketing
[email protected]

Investor Relations:
Jeff Mack
Chief Financial
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/potrero-medical-receives-fda-breakthrough-device-designation-for-accuryn-aki-predict-algorithm-301622742.html

SOURCE Potrero Medical, Inc.